European Union:
Guidance From The EU EMA And UK MHRA On Clinical Trials During The COVID-19 Pandemic
02 April 2020
Arnold & Porter
To print this article, all you need is to be registered or login on Mondaq.com.
The EMA and the competent authorities of the EU Member States
have issued guidance to manage the conduct of clinical trials and
the supply of medicinal products during the COVID-19 pandemic. This
Guidance is particularly important for all
sponsors conducting studies in the EU and for pharmaceutical
companies supplying medicines in the EU. We
discuss the key elements and practical implications for the
concerned pharmaceutical companies in our recent advisory.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from European Union
Elderly Care FAQ
Wrigleys Solicitors
These FAQs cover topics related to caring for elderly relatives. It discusses how to place an elderly person in a care home, the absence of legal obligation for family members to provide long-term care...
Food Law | UK Regulatory Outlook March 2024
Osborne Clarke
Scotland launches consultation on stricter HFSS restrictions | FSA launch campaign on allergy risks with vegan labelling | Consultation launched on fairer food labelling...